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NOTES FROM THE FIELD

Expressway to Cancer Clinical Trials: Reducing Administrative Barriers to Enrollment
Audra Putt, MPH, CPH, Michigan Department of Health and Human Services
For nearly 20 years, the Michigan Cancer Consortium (MCC) has been involved in
efforts with a variety of stakeholders to increase cancer patient participation in clinical trials. In
2001, the MCC partnered with the Michigan Working Group to Improve Cancer Outcomes on
the development of the Consensus Guidelines for Healthcare Coverage of Routine Patient Care
Cost Associated with Oncology Clinical Trials. The goal of this Consensus Agreement’s creation
was to increase participation in specific cancer-related clinical trials by supporting the
predictability of payment for clinical trial services. The voluntary Consensus Agreement includes
a framework detailing third party payer coverage of patient costs in relation to their benefit plan
for clinical trial enrollment. Members of the Michigan Association of Health Plans supported the
Consensus Agreement and agreed to increase participation in cancer-related clinical trials
through coverage of routine costs associated with participation. A 2015 assessment supported by
the MCC found clinical trial coverage through larger Michigan health plans (including Medicaid
and Medicare) generally aligns with the Consensus Agreement.
With changes related to health care coverage through the Affordable Care Act and
advancements in treatment, the MCC Board of Directors selected increasing cancer clinical trial
enrollment as the 2016-2017 priority under the Cancer Plan for Michigan’s Diagnosis and
Treatment Goal in 2016. The MCC Clinical Trials Priority Workgroup was tasked with
developing a project to support this effort. The workgroup convened with the goal to ensure
Michigan residents with cancer who want to join a clinical trial can do so with fewer barriers. In
2016, 7 percent of Michigan adults who reported a cancer diagnosis also reported participating in
cancer treatment clinical trials (Michigan Department of Health and Human Services, 2016).
The workgroup began by surveying stakeholders with the MCC and Michigan Society of
Hematology and Oncology (MSHO) to assess barriers to clinical trial enrollment. Survey results
indicated that providers had concerns with the sometimes-lengthy clinical trial enrollment
process. As a result, the workgroup decided their project would address prior authorization
concerns. Insurers often require prior authorization for cancer clinical trial enrollment, and ask
for different pieces of information. This can lead to communication barriers between providers
and insurers. In some instances, patient enrollment can be delayed by weeks while prior
authorization is approved. The workgroup project focused on facilitating more rapid response to
prior authorization requests by creating a fax cover sheet that could be shared with practitioners
and used as a “heads up” when enrolling patients in cancer clinical trials.
The fax cover sheet was created for use when a health insurance carrier requires prior
authorization for participation in a cancer clinical trial. It asks for such information as why the
patient is eligible to participate, the therapeutic purpose for conducting the trial, and whether the
trial is federally funded (see Appendix A for the fax cover sheet). Use of the fax cover sheet
intends to simplify the prior authorization process and reduce the time needed to prepare and
receive approval for authorization, thus decreasing the administrative burden for providers and
insurers. The MCC Board of Directors approved the fax cover sheet in August 2016 and made it
available as a fillable form on the MCC Website.
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After development of the fax cover sheet, the workgroup established a promotion plan for
sharing it with various stakeholders and partners. Steps were taken to promote the fax cover
sheet at the MCC Annual Meeting, on the MCC Website, at hospital cancer committee meetings,
and with partner newsletters. Following promotion, an evaluation plan for determining the cover
sheet’s reach was also established. In 2017, it was downloaded from the MCC website 261 times.
Questions about knowledge and use of the fax cover sheet were included in the 2017 MCC
Annual Survey. MSHO members were also surveyed on similar questions in the fall of 2017.
The results from both surveys (Figure 1) indicated there is still work to be done with promoting
the fax cover sheet.
Michigan Cancer Consortium
Member Survey

Michigan Society of
Hematology and Oncology
Member Survey
111
21 (18.9%)
12 (10.9%)

Number of respondents (N=)
86
Aware of the cover sheet
23 (26.7%)
Used the cover sheet in their
3 (3.5%)
office
Figure 1. Partner Knowledge and Use of the Clinical Trials Fax Cover Sheet Form

Over the next two years, the workgroup will continue to promote cancer clinical trial
enrollment. A new project will be undertaken by the workgroup to develop infographics for
patients and primary care providers, detailing the benefits of clinical trial enrollment. To support
health equity, the infographics will meet accessibility guidelines. The MCC and Clinical Trials
Priority Workgroup will remain dedicated to providing support and resources to increase the
number of Michigan adults with cancer who participate in cancer clinical trials.
This publication was supported by the Cooperative Agreement NU58DP006334 from the Centers for Disease
Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent
the official views of the Centers for Disease Control and Prevention.
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Appendix A: MCC Clinical Trials Cover Sheet
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